Market Overview

Rexahn Pharma Expands Intellectual Property Related to Class of Anti-Cancer Isoquinolinamine Compounds

Related RNN
Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin(R) at the 14th International Kidney Cancer Symposium
Rexahn Pharmaceuticals Presents Preliminary Clinical Data for Supinoxin(TM) and RX-3117 Oncology Programs at the European Cancer Congress 2015

Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has significantly expanded its intellectual property (IP) around isoquinolinamine, a class of potent anti-cancer compounds. Rexahn has been issued a continuation patent US 8,314,123 for US 8,034,829 to cover more new isoquinolinamine compounds and their pharmaceutical composition and method for producing an anti-tumor effect.

Posted-In: News FDA


Related Articles (RNN)

Get Benzinga's Newsletters